DAFTAR PUSTAKA

1. Alan, E. (2012). REGULASI EKSPRESI GEN dan Real Time PCR. *Tinjauan Pustaka*, *V*.

2. APA. (2013). *The Diagnostic and Statistical Manual of Mental Disorders* (5th ed.). Washington DC: American Psychiatric Association Publishing.

3. Barr, A. . et al. (2006). The need for speed: an update on methamphetamine addiction. *J Psychiatry Neurosci*, *31*(5), 301–313.

4. BDNF Gene. (n.d.). *Genetics Home Reference*. Retrieved from https://ghr.nlm.nih.gov/gene/BDNF

5. Bevins, K. M. G. & T. D. L. S. M. W. & M. L. & S. F. S. H. E. G. & G. C. & R. A. (2012). *Methamphetamine-Associated Psychosis*. New York: Neuroimmune Pharmacol.

6. CC.; Dyer, K. (2009). A review of the clinical pharmacology of methamphetamine. *Addiction*, *104*(7), 1085–1099. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/ j.1360-0443.2009.02564.x/full

7. Daniel F Hermens, Dan I Lubman, Philip B Ward, Sharon L Naismith, I. B. H. (2009). Amphetamine psychosis: a model for studying. *MJA*, *190*.

8. Darke, S.; Kaye, S.; McKetin, R.; Duflou, J. (2008). Major physical and psychological harms of methamphetamine use. *Drug Alcohol Rev*, *27*(3), 253–262.

9. Gabbard, G. (2014). *Psychodynamic Psychiatry in Clinical Practice* (5th ed.). Virginia: American Psychiatric Association Publishing.

10. Hashimoto K, Tsukada H, N. S. et al. (2004). Protective effects of nacetyl- l-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. *Neuropsychopharmacology*, *29*, 2018–2023.

11. Hatta, M. (2018). *Pelatihan Aplikasi Teknik Biologi Molekular dan Imunologi dalam Penelitian Bidang Kesehatan*. Makassar: Laboratorium Biologi Molekular dan Imunologi, FK UNHAS.

12. HO, S. O. & M. (2006). *Becker's rational addiction theory: an empirical test with price elasticities for distilled spirits*. Norway: University of Oslo and Norwegian Institute.

13. Joewana, S. (2004). *Gangguan Mental dan Perilaku Akibat Penggunaan Zat Psikoaktif : Penyalahgunaan Napza/Narkoba* (2nd ed.). Jakarta: ECG.

14. John. (2017). *PCP Direct ELISA. Catalog Number MBS580067*.

15. John Brick, C. K. E. (1998). *Drug, The Brain, and Behaviour*. New York: The Haworth Press Inc.

16. Kita T, Wagner GC, N. T. (2003). Current research on methamphetamine- induced neurotoxicity: animal models of monoamine disruption. *J Pharmacol Sci*, *92*, 178–195.

17. Long DJ II, J. A. (2000). NRHQuinone oxidoreductase2 (NQO2). *ChemBiol Interact*, *129*, 99–112.

18. Maslim, R. (2013). *Pedoman Penggolongan Diagnostik Gangguan Jiwa (PPDGJ) III*. Jakarta: Bagian Ilmu Kedokteran Jiwa FK UNIKA Atma Jaya.

19. Michelle, Lopez, C. (2011). Tahapan Ekspresi Gen. *Riview Article*, *32*.

20. Mishra, A. M. R. T. . S. J. vonk. (2018). *Encyclopedia of Animal Cognition and Behavior*. New York: Springer International Publishing.

21. Muhammad, W. (2017). Ekspresi Gen Menggunakan Real-Time PCR. *Tinajaun Pustaka*, *IV*, 39–50.

22. Neil A Campbell, Jane B. Reece, dan L. G. M. (2002). *Biologi*. Jakarta: Erlangga.

23. NIDA. (2008). *Genetics of addiction: A research update*. Retrieved from http://www.drugabuse.gov/tib/genetics/html

24. Ohgake, S. K. H. E. S. (2005). Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. *Addiction Biology*, *10*, 145–148. https://doi.org/10.1080/13556210500123423

25. Okubo T, Harada S, Higuchi S, M. S. (2003). Association analysesbetween polymorphisms of the phase II detoxification enzymes(GTSM1, NQO1, NQO2) and alcohol withdrawal symptoms. *AlcoholClin Exp Res*, *27*(8), 68–71.

26. Oyler JM, Cone EJ, Joseph RE, Moolchan ET, H. M. (2002). Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of

methamphetamine to humans. Retrieved August 23, 2018, from http://www.clinchem.org/cgi

27. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, S. D. (2000). Nad(p)h:Quinone oxidoreductase 1 (nqo1): Chemoprotection, bioactivation, gene regulation and genetic polymorphisms. *Chem Biol Interact*, *129*, 77–79.

28. Rxlist.com. (n.d.). Desoxyn (Methamphetamine Hydrochloride) Drug Information: User Reviews, Side Effects, Drug Interactions and Dosage. Retrieved January 9, 2011, from http://www.rxlist.com/ desoxyn-drug.htm

29. Suharsono, S., & Fmipa, B. (2015). Struktur dan Ekspresi Gen, 1–18.

30. Suryo. (1996). *Genetika*. Jakarta: Departemen P dan K Direktorat Jendral Pendidikan Tinggi.

31. Temmingh, J. S. A. U. H. S. F. M. H. G. S. D. W. D. J. S. H. (2016). *First-Rank Symptoms in Methamphetamine*. Cape Town: Psychopathology.

32. UNODC, L. and S. S. (2015). *The Challenge of Synthetic Drugs in East and South-East Asia and Oceania : Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances*. Vienna.

33. UU No.35 Tahun 2009 Tentang Narkotika. Indonesia.

34. GC, Carelli RM, J. M. (1985). Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. *Research Communications in Chemical Pathology and Pharmacology*, *47*(2), 221–228.

35. Lequin, RM (2005). "Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)". Clinical Chemistry. 51 (12): 2415–2418.

36. Walker, JM (1994). Basic Protein and Peptide Protocols, Volume 32. New Jersey: Humana Press Inc.

37. Barnes, L; Evian, C (2006), Life with HIV and AIDS (edisi ke-2nd), Gallo Manor: Awareness Publishing Group (Pty) Ltd.

38. Koes Irianto (2017). Biologi Molekuler, Penerbit ALFABETA, Bandung, 546-547.

39. Mochammad Hatta, Eko E. Surachmanto, Andi Asadul Islam, Syarifuddin Wahid. 2017. Expression of mRNA IL-17F and sIL-17F in atopic asthma patients. BMC Research Notes.10:202. DOI: 10.1186/s13104-017-2517-9. Published: 12 June (2017)

40. Mahmoudinasab H, Saadat M. 2016. Short-term Exposure to 50-Hz Electromagnetic Field and Alterations in NQO1 and NQO2 Expression in MCF-7 Cells. Open Access Maced J Med Sci. 2016 Dec 15; 4(4):548-550. https://doi.org/10.3889/oamjms.2016.102

41. Tomomi Yajima, Atsuhito Yagihashi, Daisuke Furuya, Hidekazu Kameshim. 1998. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clinical Chemistry 44:12. 2441–2445

42. Cui-Lan Tang and Zhi Chen. 2009. Differential gene expression between asymptomatic HBV carriers and normal adults. Hepatobiliary Pancreas Dis Int. 8(4); 383-388.

43. Kurniadi H. Wreksoatmodjo B. Napza dan Tubuh Kita. Jakarta : **Yayasan** Jendela . 2004.

44. UNODC. Amphetamine type stimulant and new psychoactive substance. In: Global synthetic drugs assement 2014. Diambil dari : http://www.unodc.org. 24 November 2015.

45. Husin AB, Siste K. Gangguan penggunaan zat. Dalam: Buku ajar psikiatri. Jakarta: FKUI; 2014.h. 143-71.

46. Saddock BJ, Sadock VA, Eds. Comprehensive Textbook of Psychiatry. Edisi X. Philadelphia, Baltimore, New York: Lippincott William & Wilkins, 2007

47. Pamusu D, Amir N, Effendi J, Khamelia, Kembaren L, Aritonang I, et al. Pedoman Nasional Pelayanan Kedokteran (PNPK) Jiwa/Psikiatri. 2012. h. 18-28

48. Direktorat Jenderal Pelayanan Medik Departemen Kesehatan RI. Pedoman Penggolongan Diagnosis Gangguan Jiwa III. Departemen Kesehatan RI, h. 103-2.

49. Hastono, Sutanto Priyo. 2007. Analisis Data Kesehatan. Modul: Fakultas Kesehatan Masyarakat. Jakarta: UI.

50. Sabri, Luknis., Hastono, Susanto Priyo. 2011. Statistik Kesehatan. Depok: Rajagrafindo Persada.

51. Sugiyono. 2015. Statistik Nonparametris Untuk Penelitian. Bandung: Alfabeta

52. Sunyoto, Danang., Setiawan, Ari. 2013. Buku Ajar: statistic Kesehatan. Yogyakarta: Nuha Medika

53. Gonzalez-Liencres et al. BMC Psychiatry 2014, 14:268; http: // www. biomedcentral.com/471-244X/14/268

54. Addington J, Addington D: Neurocognitive and social functioning in schizophrenia. Schizophr Bull 1999, 25:173–182.

55. L Waddington J, F Buckley P, Scully PJ, Lane A, O'Callaghan E, Larkin C : Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics? J Psychiatr Res 1998, 32:179–189.

56. Xu M-Q, Sun W-S, Liu B-X, Feng G-Y, Yu L, Yang L, He G, Sham P, Susser E, St Clair D, He L: Prenatal malnutrition and adult schizophrenia: further evidence from the 1959 –1961 Chinese famine. Schizophr Bull 2009, 35:568–576.

57. Brown AS: Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006, 32:200–202.

59. Bray TM, Taylor CG: Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol 1993, 71:746–751.

60. Wu D, Cederbaum AI: Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003, 27:277–284.

61. Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol 1997, 82: 291–295.

62. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP: Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109–122.

63. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H: Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19–26.

64. Boskovic M, Vovk T, Plesnicar BK, Grabnar I: Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9:301–312.

65. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M: Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721–3728.

66. Wang J-F, Shao L, Sun X, Young LT: Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009, 11:523–529.

67. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S: 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 2007, 6:141–149. 17. Yao JK, Reddy R, McElhinny LG, van Kammen DP: Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998, 32:1–8. 18.

68. Reddy R, Keshavana M, Yao JK: Reduced plasma antioxidants in first- episode patients with schizophrenia. Schizophr Res 2003, 62:205–212. 19. Dadheech G, Mishra S, Gautam S, Sharma P: Oxidative stress, α-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J

69. Clin Biochem 2006, 21:34 – 38. 20. Akyol O, Herken H, Uz E, Fadillioğlu E, Unal S, Söğüt S, Ozyurt H, Savaş HA: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/ antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:995–1005.

70. Avlović D, Tamburić V, Stojanović I, Kocić G, Jevtović T, Đorđević V: Oxidative stress as marker of positive symptoms in schizophrenia. Facta Univ 2002, 9:157–161.

71. Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A: Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuro- psychopharmacology Bol Psychiatry 2008, 32:155–159.

72. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J: Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005, 16:386–391.

73. Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, Belmonte-de-Abreu PS, Berk M, Kapczinski F: Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in

different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1677–1681.

74. Rukmini MS, D'Souza B, D'Souza V: Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian J Clin Biochem 2004, 19:114–118.

75. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY: Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003, 117:85–88.

76. Gardiner J, Barton D, Overall R, Marc J: Neurotrophic support and oxidative stress: converging effects in the normal and diseased nervous system. Neurosci 2009, 15:47.

77. Walz JC, Magalhães PV, Giglio LM, Cunha AB, Stertz L, Fries GR, Andreazza AC, Kapczinski F: Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res 2009, 43:721–723.

78. Hock C, Heese K, Hulette C, Rosenberg C, Otten U: Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived Neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000, 57:846–851.

79. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C: Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2010, 469:6–10.

80. Abeti R, Duchen MR: Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease. Neurochem Res 2012, 37:2589–2596.

81. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhart S, Braff DL, Marder SR, Green MF: Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res 2007, 90:316–324.

82. Brown EC, Tas C, Brüne M: Potential therapeutic avenues to tackle social cognition problems in schizophrenia. Expert Rev Neurother 2012, 12:71–81.

83. Tas C, Danaci AE, Cubukcuoglu Z, Brüne M: Impact of family involvement on social cognition training in clinically stable outpatients with schizophrenia – a randomized pilot study. Psychiatry Res 2012, 195:32–38.

84. Addington J, Addington D: Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res 2000, 44:47–56.

85. Couture SM, Granholm EL, Fish SC: A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. Schizophr Res 2011, 125:152–160.

86. Martínez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, Micó JA, Fernandez M, Echevarría E, Sanjuan J, Elorza J, González-Pinto A: Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012, 137:66–72.

87. Vasiliou V., Ross D., Nebert DW Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum. Genomics. 2006; 2 :329–335. [PMC free article] [PubMed] [Google Scholar]

88. Gong X., Gutala R., Jaiswal AK Quinone oxidoreductases and vitamin K metabolism. Vitam. Horm. 2008; 78 :85–101. [PubMed] [Google Scholar]

89. Traver RD, Horikoshi T., Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D., Gibson NW NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992; 52 :797–802. [PubMed] [Google Scholar]

90. Gong X., Kole L., Iskander K., Jaiswal AK NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res. 2007; 67 :5380–5388. [PubMed] [Google Scholar]

91. Tsvetkov P., Asher G., Reiss V., Shaul Y., Sachs L., Lotem J. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc. Natl. Acad. Sci. USA. 2005; 102 :5535–5540. [PMC free article] [PubMed] [Google Scholar]

92. Wu K., Knox R., Sun XZ, Joseph P., Jaiswal AK, Zhang D., Deng PS, Chen S. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 1997; 347 :221–228. [PubMed] [Google Scholar]

93. Long DJ, 2nd, Jaiswal AK NRH:quinone oxidoreductase2 (NQO2) Chem. Biol. Interact. 2000; 129 :99–112. [PubMed] [Google Scholar]

94. Knox RJ, Jenkins TC, Hobbs SM, Chen S., Melton RG, Burke PJ Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 2000; 60 :4179–4186. [PubMed] [Google Scholar]

95. Calamini B., Santarsiero BD, Boutin JA, Mesecar AD Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem. J. 2008; 413 :81–91. [PMC free article] [PubMed] [Google Scholar]

96. Mailliet F., Ferry G., Vella F., Berger S., Coge F., Chomarat P., Mallet C., Guenin SP, Guillaumet G., Viaud-Massuard MC, Yous S., Delagrange P., Boutin JA Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem. Pharmacol. 2005; 71 :74–88. [PubMed] [Google Scholar]

97. Fu Y., Buryanovskyy L., Zhang Z. Quinone reductase 2 is a catechol quinone reductase. J. Biol. Chem. 2008; 283 :23829–23835. [PMC free article] [PubMed] [Google Scholar]

98. Winger JA, Hantschel O., Superti-Furga G., Kuriyan J. The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2) BMC Struct. Biol. 2009; 9 7-6807-9-7. [PMC free article] [PubMed] [Google Scholar]

99. Middleton MR, Knox R., Cattell E., Oppermann U., Midgley R., Ali R., Auton T., Agarwal R., Anderson D., Sarker D., Judson I., Osawa T., Spanswick VJ, Davies S., Hartley JA, Kerr DJ Quinone oxidoreductase-2-mediated prodrug cancer therapy. Sci. Transl. Med. 2010; 2 :40ra50. [PubMed] [Google Scholar]

100. Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry. 2004; 43 :4538–4547. [PubMed] [Google Scholar]

101. Onyenwoke RU, Wiegel J. Iron (III) reduction: a novel activity of the human NAD(P)H:oxidoreductase. Biochem. Biophys. Res. Commun. 2007; 353 :389–393. [PubMed] [Google Scholar]

102. Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh TC, Wu JM, Zhang Z. Crystal structure of quinone reductase 2 in complex with

resveratrol. Biochemistry. 2004; 43 :11417–11426. [PMC free article] [PubMed] [Google Scholar]

103. Foster CE, Bianchet MA, Talalay P., Zhao Q., Amzel LM Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry. 1999; 38 :9881–9886. [PubMed] [Google Scholar]

104. Payton A., Miyajima F., Ollier W., Rabbitt P., Pickles A., Weiss V., Pendleton N., Horan M. Investigation of a functional quinine oxidoreductase (NQO2) polymorphism and cognitive decline. Neurobiol. Aging. 2010; 31 :351–352. [PubMed] [Google Scholar]

105. Hubackova M., Vaclavikova R., Ehrlichova M., Mrhalova M., Kodet R., Kubackova K., Vrana D., Gut I., Soucek P. Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int. J. Cancer. 2012; 130 :338–348. [PubMed] [Google Scholar]

106. Jamieson D., Cresti N., Bray J., Sludden J., Griffin MJ, Hawsawi NM, Famie E., Mould EV, Verrill MW, May FE, Boddy AV Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet. Genomics. 2011; 21 :808–819. [PubMed] [Google Scholar]

107. Mohelnikova-Duchonova B., Marsakova L., Vrana D., Holcatova I., Ryska M., Smerhovsky Z., Slamova A., Schejbalova M., Soucek P. Superoxide dismutase and nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase polymorphisms and pancreatic cancer risk. Pancreas. 2011; 40 :72–78.[PubMed] [Google Scholar]

108. Jamieson D., Wilson K., Pridgeon S., Margetts JP, Edmondson RJ, Leung HY, Knox R., Boddy AV NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clin. Cancer Res. 2007; 13 :1584–1590. [PubMed] [Google Scholar]

DAFTAR LAMPIRAN

WORKSHOP BIOLOGI MOLEKULER



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
FAKULTAS KEDOKTERAN, UNIVERSITAS HASANUDDIN

SERTIFIKAT

DIBERIKAN KEPADA :

dr. Dany H. Ludong, Sp.KJ

SEBAGAI

PESERTA

Dalam Pelatihan Aplikasi Teknik Biologi Molekular dan Imunologi
Dalam Penelitian Bidang Kesehatan yang diselenggarakan
di Laboratorium Biologi Molekuler & Imunologi
pada tanggal 23 - 24 November 2018

Ketua Penyelenggara

Prof. dr. Mochammad Hatta, Ph.D., Sp.MK (K)

SURAT PERSETUJUAN PENELITIAN DARI ATASAN



BADAN NARKOTIKA NASIONAL REPUBLIK INDONESIA
BALAI REHABILITASI BADDOKA
Jl.Batara Bira VI No. 35 Baddoka Kel. Pai, Kec. Biringkanaya,
Kota Makassar, 90243
Telepon: (0411) 513235, 513213
Fax : (0411) 513287
Email: bnnbaddoka@yahoo.com
Website: www.rehabbaddoka.bnn.go.id

Lampiran 5

SURAT PERSETUJUAN ATASAN
Nomor : B/91\ /BD/BL.02.01/ XII/2018/BDK

Yang bertanda tangan di bawah ini :

Nama : Agustinus Sollu, SH.S.S.,M.Si
Pangkat / NRP : Komisaris Besar Polisi / 67080659
Jabatan : Kepala Balai Rehabilitasi BNN Baddoka Makassar

Sebagai atasan langsung dari :

Nama : dr. Dany Harianto Ludong, Sp. KJ
Pekerjaan : Dokter Spesialis Kedokteran Jiwa, di Balai Rehabilitasi BNN Baddoka Makassar

Menyatakan menyetujui yang bersangkutan melakukan penelitian dengan judul:

ANALISIS EKSPRESI mRNA DAN KONSENTRASI PROTEIN PADA GEN NQO2 YANG MEMPENGARUHI TERJADINYA GANGGUAN PSIKOTIK PADA PENYALAHGUNA METAMFETAMIN

Kepala Balai Rehabilitasi BNN Baddoka Makassar

Agustinus Sollu, SH.S.S.,M.Si
Komisaris Besar Polisi

REKOMENDASI PERSETUJUAN ETIK



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
KOMITE ETIK PENELITIAN KESEHATAN
Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed,PhD, SpGK TELP. 08122578467[illegible] e-mail: agussalimbukhari@yahoo.com

REKOMENDASI PERSETUJUAN ETIK
Nomor : 521/UN4.6.4.5.31/ PP36/ 2019

Tanggal: 17 Juli 2019

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH19040251	No Sponsor Protokol	
Peneliti Utama	**dr. Dany Harianto Ludong**	Sponsor	
Judul Peneliti	Analisis Ekspresi mRNAdan Kadar Protein Pada NQO2 Yang Mempengaruhi Terjadinya Gangguan Psikotik Pada Penyalahguna Metamfetamin		
No Versi Protokol	2	Tanggal Versi	11 Juli 2019
No Versi PSP	2	Tanggal Versi	11 Juli 2019
Tempat Penelitian	**Balai Rehabilitasi BNN Baddoka Makassar**		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **17 Juli 2019** sampai **17 Juli 2020**	Frekuensi review lanjutan
Wakil Ketua Komisi Etik Penelitian	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:
- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

SURAT PERNYATAAN

Yang bertanda tangan di bawah ini:

Nama : Dany Harianto Ludong

Nomor Pokok : CO13172009

Program Pendidikan : Doktor (S3)

Program Studi : Ilmu Kedokteran

Menyatakan secara benar, jujur dan bertanggung jawab bahwa disertasi yang berjudul “Pengaruh Ekspresi mRNA dan Kadar Protein Gen NQO2 Terhadap Kejadian Gangguan Psikotik pada Penyalahguna Metamfetamin” adalah asli dan bukan plagiat / bebas dari plagiat.

Jika dikemudian hari ternyata disertasi ini sebagian/seluruhnya mengandung unsur plagiat, maka disertasi dibatalkan dan bersedia menerima sanksi secara hukum dari Fakultas maupun Universitas.

Demikian Surat Pernyataan ini dibuat tanpa tekanan siapapun.

Makassar, 26 Mei 2020

Mahasiswa,

Dany Harianto Ludong

PROSES WAWANCARA dan PEMERIKSAAN GEN NQO2
PADA REAL TIME POLYMERASE CHAIN REACTION (PCR)














INSTRUMEN PEMERIKSAAN KLIEN PENGGUNA MA

LEMBARAN ASESMEN (ASI)



PETUNJUK PENGISIAN

Diagnosa Kerja	Klien Memenuhi Kriteria Diagnosis :		
	F 10	:	Gangguan mental dan perilaku akibat penggunaan alkohol
	F 11	:	Gangguan mental dan perilaku akibat penggunaan opioid
	F 12	:	Gangguan mental dan perilaku akibat penggunaan kanabis
	F 13	:	Gangguan mental dan perilaku akibat penggunaan Sedatif Hipnotik
	F 14	:	Gangguan mental dan perilaku akibat penggunaan Kokain
	F 15	:	Gangguan mental dan perilaku akibat penggunaan stimulansia lainnya
	F 16	:	Gangguan mental dan perilaku akibat penggunaan halusinogenetik
	F 17	:	Gangguan mental dan perilaku akibat penggunaan tembakau
	F 18, F 19	:	Gangguan mental dan perilaku akibat zat pelarut yang mudah menguap, atau zat multipel dan zat psiko aktif lainnya.

Skala Penilaian	0 = 0 - 1	:	Tidak ada masalah yang berarti, tidak perlu intervensi
	1 = 2 - 3	:	Ada sedikit masalah, tetapi intervensi/ bantuan tidak terlalu penting
	2 = 4 - 5	:	Masalah tergolong sedang, tetapi butuh beberapa bantuan / intervensi
	3 = 6 - 7	:	Masalah serius, dibutuhkan intervensi/ bantuan
	4 = 8 - 9	:	Masalah sangat serius/ berat, sangat membutuhkan intervensi / bantuan

Kode Pekerjaan	Klasifikasi Pekerjaan Menurut Standar Internasional :		
	1	:	Anggota dewan legislatif, pejabat pemerintah - Tugas utama berhubungan dengan kebijakan pemerintahan, hukum, regulasi, dan pengawasan implementasi
	2	:	Profesional - Membutuhkan pengetahuan tingkat tinggi dalam bidang ilmu pengetahuan , atau ilmu sosial/kemanusiaan.
	3	:	Teknisi/kumpulan tenaga profesional - Membutuhkan pengetahuan teknis, pengalaman di lapangan berhubungan dengan ilmu fisika dan hayati, atau ilmu sosial/kemanusiaan.
	4	:	Juru Tulis - Melaksanakan tugas sekretariat, prosedur surat menyurat dan pekerjaan juru tulis lainnya yang berorientasi pada pelanggan.
	5	:	Jasa Servis dan penjualan - Termasuk jasa travel, katering, penjaga toko, merawat rumah, dan menjaga ketertiban.
	6	:	Pekerja terlatih di bidang pertanian dan perikanan - Termasuk petani, pembiak atau pemburu binatang, penangkapan atau pembudidaya ikan, dll.
	7	:	Keterampilan dan perdagangan - Tugas utama termasuk membangun gedung dan bangunan lain, membuat aneka produk, termasuk kerajinan tangan.
	8	:	Operator alat/pabrik dan mesin - Tugas utama termasuk mengemudi kendaraan, mengoperasikan mesin, dan merakit produk.
	9	:	Pekerja kasar - Termasuk pekerjaan sederhana dan rutin, seperti penjaja barang di jalan, penyambut tamu, pekerja kebersihan dan buruh.
	0	:	Angkatan bersenjata - Termasuk angkatan darat, angkatan laut, angkatan udara, dll. Tidak termasuk polisi non-militer, petugas pabean-pajak, tenaga cadangan militer inaktif.

BRIEF PSYCHIATRIC RATING SCALE (BPRS)

Patient Name _____ Today's Date _____

Please enter the score for the term that best describes the patient's condition.

0 = Not assessed, 1 = Not present, 2 = Very mild, 3 = Mild, 4 = Moderate, 5 = Moderately severe, 6 = Severe, 7 = Extremely severe

Score

1. SOMATIC CONCERN
   Preoccupation with physical health, fear of physical illness, hypochondriasis.
2. ANXIETY
   Worry, fear, over-concern for present or future, uneasiness.
3. EMOTIONAL WITHDRAWAL
   Lack of spontaneous interaction, isolation deficiency in relating to others.
4. CONCEPTUAL DISORGANIZATION
   Thought processes confused, disconnected, disorganized, disrupted.
5. GUILT FEELINGS
   Self-blame, shame, remorse for past behavior.
6. TENSION
   Physical and motor manifestations of nervousness, over-activation.
7. MANNERISMS AND POSTURING
   Peculiar, bizarre, unnatural motor behavior (not including tic).
8. GRANDIOSITY
   Exaggerated self-opinion, arrogance, conviction of unusual power or abilities.
9. DEPRESSIVE MOOD
   Sorrow, sadness, despondency, pessimism.
10. HOSTILITY
    Animosity, contempt, belligerence, disdain for others.
11. SUSPICIOUSNESS
    Mistrust, belief others harbor malicious or discriminatory intent.
12. HALLUCINATORY BEHAVIOR
    Perceptions without normal external stimulus correspondence.
13. MOTOR RETARDATION
    Slowed, weakened movements or speech, reduced body tone.
14. UNCOOPERATIVENESS
    Resistance, guardedness, rejection of authority.
15. UNUSUAL THOUGHT CONTENT
    Unusual, odd, strange, bizarre thought content.
16. BLUNTED AFFECT
    Reduced emotional tone, reduction in formal intensity of feelings, flatness.
17. EXCITEMENT
    Heightened emotional tone, agitation, increased reactivity.
18. DISORIENTATION
    Confusion or lack of proper association for person, place or time.



NILAI HASIL PEMERIKSAAN REAL TIME PCR

Sample	Starting Quantity (SQ)	Slope (dR)	Template	Log Template	Exp. mRNA	ER Mean	ER Std. Dev
Standard	2.10E+01	-3.361	50.000	1.69897	15.23976	15.26976	0.12767
Standard	2.09E+01	-3.361	50.000	1.69897	15.15976	15.26976	0.12767
Standard	2.11E+01	-3.361	50.000	1.69897	15.40976	15.26976	0.12767
L21	1.81E+01	-3.361	50.265	1.70127	12.35205	12.52538	0.30892
L21	1.81E+01	-3.361	50.265	1.70127	12.34205	12.52538	0.30892
L21	1.86E+01	-3.361	50.265	1.70127	12.88205	12.52538	0.30892
L22	1.98E+01	-3.361	50.316	1.70171	14.11057	14.06390	0.06429
L22	1.98E+01	-3.361	50.316	1.70171	14.09057	14.06390	0.06429
L22	1.97E+01	-3.361	50.316	1.70171	13.99057	14.06390	0.06429
L23	1.98E+01	-3.361	50.246	1.70110	14.08260	14.19926	0.11504
L23	2.00E+01	-3.361	50.246	1.70110	14.31260	14.19926	0.11504
L23	1.99E+01	-3.361	50.246	1.70110	14.20260	14.19926	0.11504
Standard	1.88E+01	-3.361	25.000	1.39794	14.05152	14.07819	0.02517
Standard	1.88E+01	-3.361	25.000	1.39794	14.10152	14.07819	0.02517
Standard	1.88E+01	-3.361	25.000	1.39794	14.08152	14.07819	0.02517
L24	1.84E+01	-3.361	50.324	1.70178	12.70033	12.64367	0.05132
L24	1.83E+01	-3.361	50.324	1.70178	12.60033	12.64367	0.05132
L24	1.84E+01	-3.361	50.324	1.70178	12.63033	12.64367	0.05132
L25	1.97E+01	-3.361	50.346	1.70196	13.96970	13.98970	0.03464
L25	1.98E+01	-3.361	50.346	1.70196	14.02970	13.98970	0.03464
L25	1.97E+01	-3.361	50.346	1.70196	13.96970	13.98970	0.03464
L26	1.73E+01	-3.361	50.035	1.69927	11.55874	11.74874	0.16643
L26	1.76E+01	-3.361	50.035	1.69927	11.86874	11.74874	0.16643
L26	1.75E+01	-3.361	50.035	1.69927	11.81874	11.74874	0.16643
Standard	1.59E+01	-3.361	12.500	1.09691	12.24329	12.40995	0.17010
Standard	1.63E+01	-3.361	12.500	1.09691	12.58329	12.40995	0.17010
Standard	1.61E+01	-3.361	12.500	1.09691	12.40329	12.40995	0.17010
L27	1.92E+01	-3.361	50.295	1.70152	13.52118	13.55451	0.07572
L27	1.94E+01	-3.361	50.295	1.70152	13.64118	13.55451	0.07572
L27	1.92E+01	-3.361	50.295	1.70152	13.50118	13.55451	0.07572
L28	2.08E+01	-3.361	49.473	1.69437	15.11523	15.10189	0.16042
L28	2.10E+01	-3.361	49.473	1.69437	15.25523	15.10189	0.16042
L28	2.06E+01	-3.361	49.473	1.69437	14.93523	15.10189	0.16042
L29	1.86E+01	-3.361	50.369	1.70216	12.91903	12.95236	0.12342
L29	1.86E+01	-3.361	50.369	1.70216	12.84903	12.95236	0.12342
L29	1.88E+01	-3.361	50.369	1.70216	13.08903	12.95236	0.12342
Standard	1.36E+01	-3.361	6.250	0.79588	10.94505	11.03505	0.08185
Standard	1.38E+01	-3.361	6.250	0.79588	11.10505	11.03505	0.08185
Standard	1.37E+01	-3.361	6.250	0.79588	11.05505	11.03505	0.08185
L30	1.91E+01	-3.361	50.331	1.70184	13.36013	13.34680	0.11060
L30	1.90E+01	-3.361	50.331	1.70184	13.23013	13.34680	0.11060
L30	1.92E+01	-3.361	50.331	1.70184	13.45013	13.34680	0.11060
L31	1.26E+01	-3.361	50.241	1.70106	6.85274	6.93608	0.27465
L31	1.24E+01	-3.361	50.241	1.70106	6.71274	6.93608	0.27465
L31	1.30E+01	-3.361	50.241	1.70106	7.24274	6.93608	0.27465
L32	1.29E+01	-3.361	50.118	1.69999	7.19632	7.39632	0.24269
L32	1.34E+01	-3.361	50.118	1.69999	7.66632	7.39632	0.24269
L32	1.30E+01	-3.361	50.118	1.69999	7.32632	7.39632	0.24269
Standard	1.17E+01	-3.361	3.125	0.49485	10.04681	10.02014	0.06429
Standard	1.16E+01	-3.361	3.125	0.49485	9.94681	10.02014	0.06429
Standard	1.17E+01	-3.361	3.125	0.49485	10.06681	10.02014	0.06429
L33	1.51E+01	-3.361	50.391	1.70235	9.40839	9.38844	0.12117
L33	1.52E+01	-3.361	50.391	1.70235	9.49839	9.38844	0.12117
L33	1.50E+01	-3.361	50.386	1.70231	9.25854	9.38844	0.12117
L34	1.34E+01	-3.361	49.695	1.69631	7.69869	7.92536	0.22030
L34	1.38E+01	-3.361	49.695	1.69631	8.13869	7.92536	0.22030
L34	1.36E+01	-3.361	49.695	1.69631	7.93869	7.92536	0.22030
L35	1.41E+01	-3.361	49.947	1.69851	8.39131	8.24464	0.13317
L35	1.38E+01	-3.361	49.947	1.69851	8.13131	8.24464	0.13317
L35	1.39E+01	-3.361	49.947	1.69851	8.21131	8.24464	0.13317
Standard	9.58E+00	-3.361	1.562	0.19368	8.92904	8.90904	0.05292
Standard	9.60E+00	-3.361	1.562	0.19368	8.94904	8.90904	0.05292
Standard	9.50E+00	-3.361	1.562	0.19368	8.84904	8.90904	0.05292
L36	1.20E+01	-3.361	50.187	1.70059	6.26431	5.91431	0.45177
L36	1.18E+01	-3.361	50.187	1.70059	6.07431	5.91431	0.45177
L36	1.11E+01	-3.361	50.187	1.70059	5.40431	5.91431	0.45177
L37	10.73000	-3.361	50.348	1.70198	5.00964	5.21630	0.24685
L37	10.87000	-3.361	50.348	1.70198	5.14964	5.21630	0.24685
L37	11.21000	-3.361	50.348	1.70198	5.48964	5.21630	0.24685
L38	14.89000	-3.361	50.212	1.70081	9.17359	9.17692	0.09504
L38	14.99000	-3.361	50.212	1.70081	9.27359	9.17692	0.09504
L38	14.80000	-3.361	50.212	1.70081	9.08359	9.17692	0.09504
Neg	N/A	N/A	N/A	#VALUE!	#VALUE!	#VALUE!	#VALUE!
Neg	N/A	N/A	N/A	#VALUE!	#VALUE!	#VALUE!	#VALUE!
Neg	N/A	N/A	N/A	#VALUE!	#VALUE!	#VALUE!	#VALUE!
L39	12.61000	-3.361	50.394	1.70238	6.88830	7.00164	0.11015
L39	12.83000	-3.361	50.394	1.70238	7.10830	7.00164	0.11015
L39	12.73000	-3.361	50.394	1.70238	7.00830	7.00164	0.11015
L40	14.17000	-3.361	50.351	1.70201	8.44955	8.34622	0.11676
L40	13.94000	-3.361	50.351	1.70201	8.21955	8.34622	0.11676
L40	14.09000	-3.361	50.351	1.70201	8.36955	8.34622	0.11676

RUMUS EKSPRESI :
SLOPE * LOG TEMPLATE + STARTING QUANTITY

SATUAN EKSPRESI :
FOLD CHANGE

Sample	Starting Quantity (SQ)	Slope (dR)	Template	Log Template	Exp. mRNA	ER Mean	ER Std. Dev
Standard	2.08E+01	-3.377	50.000	1.69897	15.09258	15.05591	0.15822
Standard	2.09E+01	-3.377	50.000	1.69897	15.19258	15.05591	0.15822
Standard	2.06E+01	-3.377	50.000	1.69897	14.88258	15.05591	0.15822
L01	1.84E+01	-3.377	50.305	1.70161	12.62366	12.62366	0.26000
L01	1.81E+01	-3.377	50.305	1.70161	12.36366	12.62366	0.26000
L01	1.86E+01	-3.377	50.305	1.70161	12.88366	12.62366	0.26000
L02	1.72E+01	-3.377	50.301	1.70158	11.46378	11.44378	0.14107
L02	1.70E+01	-3.377	50.301	1.70158	11.29378	11.44378	0.14107
L02	1.73E+01	-3.377	50.301	1.70158	11.57378	11.44378	0.14107
L03	1.87E+01	-3.377	50.173	1.70047	12.92751	13.13751	0.19313
L03	1.89E+01	-3.377	50.173	1.70047	13.17751	13.13751	0.19313
L03	1.91E+01	-3.377	50.173	1.70047	13.30751	13.13751	0.19313
Standard	1.89E+01	-3.377	25.000	1.39794	14.21916	14.35249	0.14048
Standard	1.92E+01	-3.377	25.000	1.39794	14.49916	14.35249	0.14048
Standard	1.91E+01	-3.377	25.000	1.39794	14.33916	14.35249	0.14048
L04	1.82E+01	-3.377	49.978	1.69878	12.48322	12.38322	0.10536
L04	1.81E+01	-3.377	49.978	1.69878	12.39322	12.38322	0.10536
L04	1.80E+01	-3.377	49.978	1.69878	12.27322	12.38322	0.10536
L05	1.97E+01	-3.377	50.256	1.70119	13.94509	14.05176	0.09713
L05	1.98E+01	-3.377	50.256	1.70119	14.07509	14.05176	0.09713
L05	1.99E+01	-3.377	50.256	1.70119	14.13509	14.05176	0.09713
L06	1.77E+01	-3.377	49.457	1.69423	11.98859	11.95526	0.22189
L06	1.79E+01	-3.377	49.457	1.69423	12.15859	11.95526	0.22189
L06	1.74E+01	-3.377	49.457	1.69423	11.71859	11.95526	0.22189
Standard	1.67E+01	-3.377	12.500	1.09691	12.96573	12.94240	0.09713
Standard	1.67E+01	-3.377	12.500	1.09691	13.02573	12.94240	0.09713
Standard	1.65E+01	-3.377	12.500	1.09691	12.83573	12.94240	0.09713
L07	1.83E+01	-3.377	50.296	1.70153	12.50392	12.48725	0.04726
L07	1.82E+01	-3.377	50.296	1.70153	12.43392	12.48725	0.04726
L07	1.83E+01	-3.377	50.296	1.70153	12.52392	12.48725	0.04726
L08	1.68E+01	-3.377	50.071	1.69959	11.08050	11.02716	0.11930
L08	1.66E+01	-3.377	50.071	1.69959	10.89050	11.02716	0.11930
L08	1.69E+01	-3.377	50.071	1.69959	11.11050	11.02716	0.11930
L09	1.72E+01	-3.377	50.116	1.69998	11.48918	11.73918	0.21794
L09	1.76E+01	-3.377	50.116	1.69998	11.83918	11.73918	0.21794
L09	1.76E+01	-3.377	50.116	1.69998	11.88918	11.73918	0.21794
Standard	1.43E+01	-3.377	6.250	0.79588	11.65231	11.64898	0.12503
Standard	1.42E+01	-3.377	6.250	0.79588	11.52231	11.64898	0.12503
Standard	1.45E+01	-3.377	6.250	0.79588	11.77231	11.64898	0.12503
L10	2.04E+01	-3.377	50.274	1.70134	14.69456	14.75456	0.20664
L10	2.07E+01	-3.377	50.274	1.70134	14.98456	14.75456	0.20664
L10	2.03E+01	-3.377	50.274	1.70134	14.58456	14.75456	0.20664
L11	1.99E+01	-3.377	50.312	1.70167	14.12346	14.25015	0.11154
L11	2.00E+01	-3.377	50.312	1.70167	14.29346	14.25015	0.11154
L11	2.01E+01	-3.377	50.309	1.70165	14.33354	14.25015	0.11154
L12	1.79E+01	-3.377	50.175	1.70049	12.11745	11.97412	0.34790
L12	1.73E+01	-3.377	50.175	1.70049	11.57745	11.97412	0.34790
L12	1.80E+01	-3.377	50.175	1.70049	12.22745	11.97412	0.34790
Standard	1.18E+01	-3.377	3.125	0.49485	10.12889	10.02889	0.19975
Standard	1.15E+01	-3.377	3.125	0.49485	9.79889	10.02889	0.19975
Standard	1.18E+01	-3.377	3.125	0.49485	10.15889	10.02889	0.19975
L13	1.70E+01	-3.377	50.087	1.69973	11.22003	11.22336	0.13503
L13	1.71E+01	-3.377	50.087	1.69973	11.36003	11.22336	0.13503
L13	1.68E+01	-3.377	50.087	1.69973	11.09003	11.22336	0.13503
L14	1.76E+01	-3.377	49.766	1.69693	11.82946	11.89279	0.12741
L14	1.78E+01	-3.377	49.766	1.69693	12.03946	11.89279	0.12741
L14	1.75E+01	-3.377	49.766	1.69693	11.80946	11.89279	0.12741
L15	1.82E+01	-3.377	49.976	1.69876	12.48328	12.44662	0.04041
L15	1.81E+01	-3.377	49.976	1.69876	12.40328	12.44662	0.04041
L15	1.82E+01	-3.377	49.976	1.69876	12.45328	12.44662	0.04041
Standard	1.07E+01	-3.377	1.562	0.19368	9.99594	9.91261	0.11930
Standard	1.04E+01	-3.377	1.562	0.19368	9.77594	9.91261	0.11930
Standard	1.06E+01	-3.377	1.562	0.19368	9.96594	9.91261	0.11930
L16	1.94E+01	-3.377	49.971	1.69872	13.68343	13.53676	0.13650
L16	1.93E+01	-3.377	49.971	1.69872	13.51343	13.53676	0.13650
L16	1.92E+01	-3.377	49.971	1.69872	13.41343	13.53676	0.13650
L17	18.44000	-3.377	49.873	1.69787	12.70631	12.38297	0.29263
L17	18.04000	-3.377	49.873	1.69787	12.30631	12.38297	0.29263
L17	17.87000	-3.377	49.873	1.69787	12.13631	12.38297	0.29263
L18	18.31000	-3.377	50.124	1.70005	12.56895	12.63895	0.14799
L18	18.55000	-3.377	50.124	1.70005	12.80895	12.63895	0.14799
L18	18.28000	-3.377	50.124	1.70005	12.53895	12.63895	0.14799
Neg	N/A	N/A	N/A	#VALUE!	#VALUE!	#VALUE!	#VALUE!
Neg	N/A	N/A	N/A	#VALUE!	#VALUE!	#VALUE!	#VALUE!
Neg	N/A	N/A	N/A	#VALUE!	#VALUE!	#VALUE!	#VALUE!
L19	19.25000	-3.377	50.283	1.70142	13.50430	13.33430	0.15716
L19	18.94000	-3.377	50.283	1.70142	13.19430	13.33430	0.15716
L19	19.05000	-3.377	50.283	1.70142	13.30430	13.33430	0.15716
L20	18.72000	-3.377	50.209	1.70078	12.97646	12.90646	0.15716
L20	18.47000	-3.377	50.209	1.70078	12.72646	12.90646	0.15716
L20	18.76000	-3.377	50.209	1.70078	13.01646	12.90646	0.15716

RUMUS EKSPRESI :
SLOPE * LOG TEMPLATE + STARTING QUANTITY

SATUAN EKSPRESI :
FOLD CHANGE

HASIL PEMERIKSAAN REAL TIME PCR

Sampel Nomor 1 – 30: Kelompok Kontrol

No	Sampel	Kontrol	Ekspresi (fold change)
1	L01	MA Non Psikotik	12.624
2	L02	MA Non Psikotik	11.444
3	L03	MA Non Psikotik	13.138
4	L04	MA Non Psikotik	12.383
5	L05	MA Non Psikotik	14.052
6	L06	MA Non Psikotik	11.955
7	L07	MA Non Psikotik	12.487
8	L08	MA Non Psikotik	11.027
9	L09	MA Non Psikotik	11.739
10	L10	MA Non Psikotik	14.755
11	L11	MA Non Psikotik	11.749
12	L12	MA Non Psikotik	13.555
13	L13	MA Non Psikotik	15.102
14	L14	MA Non Psikotik	12.952
15	L15	MA Non Psikotik	13.347

No	Sampel	Kontrol	Ekspresi (fold change)
16	L16	Non Pengguna	13.537
17	L17	Non Pengguna	12.383
18	L18	Non Pengguna	12.639
19	L19	Non Pengguna	13.334
20	L20	Non Pengguna	12.906
21	L21	Non Pengguna	12.525
22	L22	Non Pengguna	14.064
23	L23	Non Pengguna	14.064
24	L24	Non Pengguna	11.739
25	L25	Non Pengguna	14.064
26	L26	Non Pengguna	14.250
27	L27	Non Pengguna	11.974
28	L28	Non Pengguna	11.974
29	L29	Non Pengguna	11.893
30	L30	Non Pengguna	11.893

Sampel Nomor 31 – 60: Kelompok Kasus

NO	Sampel	Ekspresi (Fold change)
31	L31	6.936
32	L32	7.396
33	L33	9.388
34	L34	7.925
35	L35	8.245
36	L36	5.914
37	L37	5.216
38	L38	9.177
39	L39	7.002
40	L40	8.346
41	L41	8.034
42	L42	6.088
43	L43	8.289
44	L44	7.719
45	L45	8.092

NO	Sampel	Ekspresi (Fold change)
46	L46	8.239
47	L47	9.653
48	L48	9.170
49	L49	5.015
50	L50	6.926
51	L53	6.460
52	L52	8.430
53	L53	5.449
54	L54	6.080
55	L55	7.637
56	L56	4.722
57	L57	8.947
58	L58	9.807
59	L59	5.537
60	L60	8.074

PEMERIKSAAN KADAR PROTEIN GEN NQO2 DENGAN SANDWICH ELISA














NILAI PEMERIKSAAN SANDWICH ELISA

Human Ribosyldihydronicotinamide Dehydrogenase [Quinone] (NQO2) ELISA Kit Cat.No: MBS9321059

Layout

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	Standard 1	Standard 1	Sample-1	Sample-1	Sample-2	Sample-2	Sample-3	Sample-3	Sample-4	Sample-4	Sample-5	Sample-5
B	Standard 2	Standard 2	Sample-6	Sample-6	Sample-7	Sample-7	Sample-8	Sample-8	Sample-9	Sample-9	Sample-10	Sample-10
C	Standard 3	Standard 3	Sample-11	Sample-11	Sample-12	Sample-12	Sample-13	Sample-13	Sample-14	Sample-14	Sample-15	Sample-15
D	Standard 4	Standard 4	Sample-16	Sample-16	Sample-17	Sample-17	Sample-18	Sample-18	Sample-19	Sample-19	Sample-20	Sample-20
E	Standard 5	Standard 5	Sample-21	Sample-21	Sample-22	Sample-22	Sample-23	Sample-23	Sample-24	Sample-24	Sample-25	Sample-25
F	Standard 6	Standard 6	Sample-26	Sample-26	Sample-27	Sample-27	Sample-28	Sample-28	Sample-29	Sample-29	Sample-30	Sample-30
G	Standard 7	Standard 7	Sample-31	Sample-31	Sample-32	Sample-32	Sample-33	Sample-33	Sample-34	Sample-34	Sample-35	Sample-35
H	NEG	NEG	Sample-36	Sample-36	Sample-37	Sample-37	Sample-38	Sample-38	Sample-39	Sample-39	Sample-40	Sample-40

Sampel

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	hNQO2#1	8	S01	S01	S02	S02	S03	S03	S04	S04	S05	S05
B	hNQO2#2	4	S06	S06	S07	S07	S08	S08	S09	S09	S10	S10
C	hNQO2#3	2	S11	S11	S12	S12	S13	S13	S14	S14	S15	S15
D	hNQO2#4	1	S16	S16	S17	S17	S18	S18	S19	S19	S20	S20
E	hNQO2#5	0.5	S31	S31	S32	S32	S33	S33	S34	S34	S35	S35
F	hNQO2#6	0.25	S36	S36	S37	S37	S38	S38	S39	S39	S40	S40
G	NEG	0	S41	S41	S42	S42	S43	S43	S44	S44	S45	S45
H	Blank	0	S46	S46	S47	S47	S48	S48	S49	S49	S50	S50

Optic Density

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	0.984	1.128	0.104	0.113	0.138	0.121	0.111	0.112	0.111	0.117	0.141	0.132
B	0.687	0.676	0.108	0.112	0.147	0.131	0.114	0.105	0.117	0.119	0.144	0.148
C	0.370	0.366	0.111	0.107	0.133	0.116	0.115	0.107	0.107	0.116	0.146	0.132
D	0.220	0.186	0.123	0.114	0.13	0.125	0.112	0.125	0.116	0.124	0.143	0.129
E	0.139	0.130	0.086	0.084	0.091	0.097	0.097	0.104	0.097	0.112	0.108	0.095
F	0.105	0.089	0.095	0.092	0.093	0.09	0.083	0.091	0.087	0.113	0.108	0.111
G	0.054	0.050	0.083	0.088	0.086	0.09	0.089	0.098	0.090	0.109	0.122	0.115
H	0.048	0.316	0.086	0.101	0.097	0.088	0.083	0.086	0.088	0.115	0.098	0.096

Human Ribosyldihydronicotinamide Dehydrogenase [Quinone] (NQO2) ELISA Kit Cat.No: MBS9321059

Layout

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	Standard 1	Standard 1	Sample-1	Sample-1	Sample-2	Sample-2	Sample-3	Sample-3	Sample-4	Sample-4	Sample-5	Sample-5
B	Standard 2	Standard 2	Sample-6	Sample-6	Sample-7	Sample-7	Sample-8	Sample-8	Sample-9	Sample-9	Sample-10	Sample-10
C	Standard 3	Standard 3	Sample-11	Sample-11	Sample-12	Sample-12	Sample-13	Sample-13	Sample-14	Sample-14	Sample-15	Sample-15
D	Standard 4	Standard 4	Sample-16	Sample-16	Sample-17	Sample-17	Sample-18	Sample-18	Sample-19	Sample-19	Sample-20	Sample-20
E	Standard 5	Standard 5	Sample-21	Sample-21	Sample-22	Sample-22	Sample-23	Sample-23	Sample-24	Sample-24	Sample-25	Sample-25
F	Standard 6	Standard 6										
G	Standard 7	Standard 7										
H	NEG	NEG										

Sampel

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	hNQO2#1	8	S21	S21	S22	S22	S23	S23	S24	S24	S25	S25
B	hNQO2#2	4	S26	S26	S27	S27	S28	S28	S29	S29	S30	S30
C	hNQO2#3	2	S51	S51	S52	S52	S53	S53	S54	S54	S55	S55
D	hNQO2#4	1	S56	S56	S57	S57	S58	S58	S59	S59	S60	S60
E	hNQO2#5	0.5	S33	S33	S34	S34	S35	S35	S45	S45	S49	S49
F	hNQO2#6	0.25										
G	NEG	0										
H	Blank	0										

Optic Density

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	1.253	0.977	0.125	0.141	0.143	0.131	0.133	0.119	0.129	0.119	0.141	0.129
B	0.733	0.671	0.133	0.125	0.141	0.137	0.108	0.134	0.152	0.130	0.117	0.137
C	0.358	0.371	0.103	0.077	0.076	0.094	0.098	0.092	0.101	0.093	0.096	0.070
D	0.194	0.204	0.096	0.090	0.103	0.073	0.107	0.091	0.077	0.095	0.096	0.086
E	0.138	0.131	0.083	0.091	0.112	0.136	0.088	0.079	0.125	0.103	0.078	0.083
F	0.102	0.095	0.047	0.045	0.044	0.047	0.043	0.044	0.044	0.043	0.047	0.046
G	0.053	0.051	0.043	0.046	0.046	0.042	0.045	0.043	0.045	0.044	0.048	0.046
H	0.046	0.048	0.046	0.043	0.045	0.045	0.042	0.045	0.048	0.046	0.043	0.047

Human Ribosyldihydronicotinamide Dehydrogenase [Quinone] (NQO2) ELISA Kit Cat.No: MBS9321059

Mean / STD DEV OD

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	1.056	0.102	0.109	0.006	0.130	0.012	0.112	0.001	0.114	0.004	0.137	0.006
B	0.682	0.008	0.110	0.003	0.139	0.011	0.110	0.006	0.118	0.001	0.146	0.003
C	0.368	0.003	0.109	0.003	0.125	0.012	0.111	0.006	0.112	0.006	0.139	0.010
D	0.203	0.024	0.119	0.006	0.128	0.004	0.119	0.009	0.120	0.006	0.136	0.010
E	0.135	0.006	0.085	0.001	0.094	0.004	0.101	0.005	0.105	0.011	0.102	0.009
F	0.097	0.011	0.094	0.002	0.092	0.002	0.087	0.006	0.100	0.018	0.110	0.002
G	0.052	0.003	0.086	0.004	0.088	0.003	0.094	0.006	0.100	0.013	0.119	0.005
H	0.182	0.190	0.094	0.011	0.093	0.006	0.085	0.002	0.102	0.019	0.097	0.001

Sampel / Concentration (pg/ml)

	1	2	3	4	5	6	7	8	9	10	11	12
A	hNQO2#1	8	S01	0.2319	S02	0.39379	S03	0.25503	S04	0.2743	S05	0.44775
B	hNQO2#2	4	S06	0.24346	S07	0.46702	S08	0.23961	S09	0.30514	S10	0.52099
C	hNQO2#3	2	S11	0.23576	S12	0.35524	S13	0.25117	S14	0.25503	S15	0.46702
D	hNQO2#4	1	S16	0.30899	S17	0.37837	S18	0.30899	S19	0.32055	S20	0.4439
E	hNQO2#5	0.5	S31	0.05074	S32	0.12012	S33	0.17023	S34	0.20106	S35	0.17794
F	hNQO2#6	0.25	S36	0.11627	S37	0.10085	S38	0.06616	S39	0.16637	S40	0.23961
G	NEG	0	S41	0.05459	S42	0.07387	S43	0.11627	S44	0.16252	S45	0.30899
H	Blank	0	S46	0.11627	S47	0.10856	S48	0.04689	S49	0.17794	S50	0.14325

Conc	OD
8	1.056
4	0.682
2	0.368
1	0.203
0.5	0.135
0.25	0.097
0	0.052



Human Ribosyldihydronicotinamide Dehydrogenase [Quinone] (NQO2) ELISA Kit Cat.No: MBS9321059

Mean / STD DEV OD

<>	1	2	3	4	5	6	7	8	9	10	11	12
A	1.115	0.195	0.133	0.011	0.137	0.008	0.126	0.010	0.124	0.007	0.135	0.008
B	0.702	0.044	0.129	0.006	0.139	0.003	0.121	0.018	0.141	0.016	0.127	0.014
C	0.365	0.009	0.090	0.018	0.085	0.013	0.095	0.004	0.097	0.006	0.083	0.018
D	0.199	0.007	0.093	0.004	0.088	0.021	0.099	0.011	0.086	0.013	0.091	0.007
E	0.135	0.005	0.087	0.006	0.124	0.017	0.084	0.006	0.114	0.016	0.081	0.004
F	0.099	0.005										
G	0.052	0.001										
H	0.047	0.001										

Sampel / Concentration (pg/ml)

	1	2	3	4	5	6	7	8	9	10	11	12
A	hNQO2#1	8	S21	0.43975	S22	0.46897	S23	0.38861	S24	0.374	S25	0.45436
B	hNQO2#2	4	S26	0.41052	S27	0.48358	S28	0.35208	S29	0.49819	S30	0.39591
C	hNQO2#3	2	S51	0.1256	S52	0.08907	S53	0.16213	S54	0.17674	S55	0.07446
D	hNQO2#4	1	S56	0.14752	S57	0.11099	S58	0.19135	S59	0.09638	S60	0.13291
E	hNQO2#5	0.5	S33	0.10368	S34	0.374	S35	0.07811	S45	0.30094	S49	0.0562
F	hNQO2#6	0.25										
G	NEG	0										
H	Blank	0										

Conc	OD
8	1.115
4	0.702
2	0.365
1	0.199
0.5	0.135
0.25	0.099
0	0.052



HASIL PEMERIKSAAN SANDWICH ELISA

Sampel Nomor 1 – 30: Kelompok Kontrol

No.	Sampel	Kontrol	Ekspresi (fold change)
1	L01	MA Non Psikotik	2.3190056
2	L02	MA Non Psikotik	3.9378903
3	L03	MA Non Psikotik	2.5502749
4	L04	MA Non Psikotik	2.7429993
5	L05	MA Non Psikotik	4.4775186
6	L06	MA Non Psikotik	2.4346403
7	L07	MA Non Psikotik	4.6702429
8	L08	MA Non Psikotik	2.3960954
9	L09	MA Non Psikotik	3.0513582
10	L10	MA Non Psikotik	5.2098711
11	L11	MA Non Psikotik	4.1052490
12	L12	MA Non Psikotik	4.8358206
13	L13	MA Non Psikotik	3.5207916
14	L14	MA Non Psikotik	4.9819350
15	L15	MA Non Psikotik	3.9591346

No.	Sampel	Kontrol	Ekspresi (fold change)
16	L16	Non Pengguna	2.3575505
17	L17	Non Pengguna	3.5524416
18	L18	Non Pengguna	2.5117300
19	L19	Non Pengguna	2.5117300
20	L20	Non Pengguna	2.5502749
21	L21	Non Pengguna	4.6702429
22	L22	Non Pengguna	3.7837108
23	L23	Non Pengguna	3.0899031
24	L24	Non Pengguna	3.2055377
25	L25	Non Pengguna	4.4389737
26	L26	Non Pengguna	4.3974776
27	L27	Non Pengguna	4.6897063
28	L28	Non Pengguna	3.8860774
29	L29	Non Pengguna	3.7399631
30	L30	Non Pengguna	4.5435920

Sampel Nomor 31 – 60: Kelompok Kasus

NO	Sampel	Ekspresi (Fold change)
31	L31	6.936
32	L32	7.396
33	L33	9.388
34	L34	7.925
35	L35	8.245
36	L36	5.914
37	L37	5.216
38	L38	9.177
39	L39	7.002
40	L40	8.346
41	L41	8.034
42	L42	6.088
43	L43	8.289
44	L44	7.719
45	L45	8.092

NO	Sampel	Ekspresi (Fold change)
46	L46	8.239
47	L47	9.653
48	L48	9.170
49	L49	5.015
50	L50	6.926
51	L53	6.460
52	L52	8.430
53	L53	5.449
54	L54	6.080
55	L55	7.637
56	L56	4.722
57	L57	8.947
58	L58	9.807
59	L59	5.537
60	L60	8.074

HASIL ANALISA SPSS 24

A. ANALISIS EKSPRESI mRNA GEN NQO2 PADA PEMERIKSAAN RT PCR

1. UJI T INDEPENDEN (INDEPENDENT SAMPLES TEST)

Uji T mula-mula dilakukan pada kelompok kontrol, antara klien pengguna MA tanpa psikotik (sampel nomor 1 sampai 15) dengan orang normal (bukan pengguna) (sampel nomor 16 sampai 30).

Group Statistics

	Normal	N	Mean	Std. Deviation	Std. Error Mean
met non psikotik	1	15	12.82060	1.192788	.307976
	2	15	12.93387	.928151	.239647

Nilai mean kelompok MA Non Psikotik = 12,82060, sedangkan kelompok orang normal / bukan pengguna = 12,93387.

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Ekspresi mRNA	Equal variances assumed	.760	.391	-.290	28	**.774**	-.113267	.390231	-.912619	.686086
	Equal variances not assumed			-.290	26.406	**.774**	-.113267	.390231	-.914799	.688266

Hasil uji T memperlihatkan bahwa Nilai Sig. (2-tailed) yaitu 0,774, berarti lebih besar dari nilai alpha = 0,05 (>0,05).

Kemudian dilanjutkan Uji T antara kelompok kontrol keseluruhan (sampel nomor 1 sampai 30) dengan kelompok kasus (sampel nomor 31 sampai 60).

T-Test

Group Statistics

	KELOMPOK	N	Mean	Std. Deviation	Std. Error Mean
EKSPRESI RT- PCR	KONTROL	30	12,87723	1,051683	,192010
	KASUS	30	7,46377	1,454805	,265610

Nilai Mean Ekspresi RT-PCR pada kelompok kasus (7,46377), lebih kecil dari pada kelompok kontrol (12,87723).

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
EKSPRESI RT- PCR	Equal variances assumed	4,209	,045	16,517	58	,000	5,413467	,327745	4,757415	6,069519
	Equal variances not assumed			16,517	52,808	,000	5,413467	,327745	4,756039	6,070895

Hasil Uji T menunjukkan nilai *sig.(2-tailed)* = 0,000, berarti nilai tersebut lebih kecil dari nilai alpha = 0.05 (<0.05).

2. ROC CURVE

Case Processing Summary

KELOMPOK	Valid N (listwise)
Positive[a]	30
Negative	30

Larger values of the test result variable(s) indicate stronger evidence for a positive actual state.

Interpretasi:

Pada tabel di atas menunjukkan bahwa jumlah subjek kelompok kontrol (Positive) adalah 30 dari 60 subjek. Dengan demikian prevalensinya adalah 50%.



Interpretasi:

Kurva ROC (Receiver Operating Characteristic) menunjukkan bahwa skor ekspresi RT-PCR mempunyai nilai diagnostic yang baik karena kurva jauh dari garis 50% dan mendekati 100%.

Area Under the Curve

Test Result Variable(s): EKSPRESI RT- PCR

Area	Std. Error[a]	Asymptotic Sig.[b]	Asymptotic 95% Confidence Interval	
			Lower Bound	Upper Bound
1,000	,000	,000	1,000	1,000

a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5

Interpretasi:

Nilai AUC (Area under the Curve) adalah 100% (IK95% 100% - 100%). Nilai AUC 100% artinya apabila skor ekspresi RT-PCR digunakan

sebagai alat bantu diagnosa terhadap ada tidaknya gejala psikotik akibat penyalahgunaan metamfetamin pada 100 orang klien, maka kesimpulan yang tepat akan diperoleh pada 100 klien.



Coordinates of the Curve
Test Result Variable(s): EKSPRESI RT- PCR

No.	Positive if Greater Than or Equal To[a]	Sensitivity	1 - Specificity
1	3,72200	1,000	1,000
2	4,86850	1,000	,967
3	5,11550	1,000	,933
4	5,33250	1,000	,900
5	5,49300	1,000	,867
6	5,72550	1,000	,833
7	5,99700	1,000	,800
8	6,08400	1,000	,767
9	6,27400	1,000	,733
10	6,69300	1,000	,700
11	6,93100	1,000	,667
12	6,96900	1,000	,633
13	7,19900	1,000	,600
14	7,51650	1,000	,567

15	7,67800	1,000	,533
16	7,82200	1,000	,500
17	7,97950	1,000	,467
18	8,05400	1,000	,433
19	8,08300	1,000	,400
20	8,16550	1,000	,367
21	8,24200	1,000	,333
22	8,26700	1,000	,300
23	8,31750	1,000	,267
24	8,38800	1,000	,233
25	8,68850	1,000	,200
26	9,05850	1,000	,167
27	9,17350	1,000	,133
28	9,28250	1,000	,100
29	9,52050	1,000	,067
30	9,73000	1,000	,033
31	10,41700	1,000	1,000
32	11,12500	,967	,000
33	11,33350	,933	,000
34	11,59150	,900	,000
35	11,74400	,867	,000
36	11,82100	,833	,000
37	11,92400	,800	,000
38	11,96450	,767	,000
39	12,17850	,733	,000
40	12,41500	,667	,000
41	12,46700	,633	,000
42	12,50600	,600	,000
43	12,57450	,567	,000
44	12,63150	,533	,000
45	12,64150	,500	,000
46	12,77500	,467	,000
47	12,92900	,433	,000
48	13,04500	,400	,000
49	13,23600	,367	,000
50	13,34050	,333	,000
51	13,44200	,300	,000
52	13,54600	,267	,000

53	13,77250	,233	,000
54	14,02100	,200	,000
55	14,05800	,167	,000
56	14,13150	,133	,000
57	14,22450	,100	,000
58	14,50250	,067	,000
59	14,92850	,033	,000
60	16,10200	,000	,000

a. The smallest cutoff value is the minimum observed test value minus 1, and the largest cutoff value is the maximum observed test value plus 1. All the other cutoff values are the averages of two consecutive ordered observed test values.

Interpretasi:

Titik potong (cut-off) yang direkomendasikan secara statistik adalah antara 9,28 sampai 9,73**,** dengan nilai sensitivitas 100% dan spesifisitas ≥ 90%.

B. ANALISIS KADAR PROTEIN PADA PEMERIKSAAN SANDWICH ELISA

9. UJI T INDEPENDEN (INDEPENDENT SAMPLES TEST)

Uji T mula-mula dilakukan pada kelompok kontrol, antara klien pengguna MA tanpa psikotik (sampel nomor 1 sampai 15) dengan orang normal (bukan pengguna) (sampel nomor 16 sampai 30).

Group Statistics

	kelompok	N	Mean	Std. Deviation	Std. Error Mean
elisa	1	15	3.679521826	1.0330177651	.2667240400
	2	15	3.633805655	.8101730502	.2091857821

Nilai mean kelompok MA Non Psikotik = 3.6752, sedangkan kelompok orang normal / bukan pengguna = 3,63387.

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Elisa	Equal variances assumed	2.011	.167	.135	28	.894	.0457	.3389696225	-.6486316248	.7400639662
	Equal variances not assumed			.135	26.495	.894	.0457	.3389696225	-.6504126403	.7418449818

Hasil uji T memperlihatkan bahwa Nilai Sig. (2-tailed) yaitu 0,894, berarti lebih besar dari nilai alpha = 0,05 (>0,05).

Kemudian dilanjutkan Uji T antara kelompok kontrol keseluruhan (sampel nomor 1 sampai 30) dengan kelompok kasus (sampel nomor 31 sampai 60).

T-Test

	KELOMPOK	N	Mean	Std. Deviation	Std. Error Mean
KONSENTRASI SANDWICH ELISA	KONTROL	30	3,6570	,91276	,16665
	KASUS	30	1,2460	,59106	,10791

Nilai Mean kadar protein Elisa pada kelompok kasus (1,2460) lebih kecil dari kelompok kontrol (3,6570).

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
KONSENTRASI SANDWICH ELISA	Equal variances assumed	10,668	,002	12,144	58	,000	2,41100	,19853	2,01359	2,80841
	Equal variances not assumed			12,144	49,684	,000	2,41100	,19853	2,01217	2,80983

Hasil Uji t menunjukkan nilai *sig(2-tailed)* (Equal variances not assumed) = 0,000, lebih kecil dari 0.05 (<0.05).

10. ROC CURVE

Case Processing Summary

KELOMPOK	Valid N (listwise)
Positive[a]	30
Negative	30

Larger values of the test result variable(s) indicate stronger evidence for a positive actual state.

Interpretasi:

Pada tabel di atas menunjukkan bahwa jumlah subjek kelompok kasus (Positive) adalah 30 dari 60 subjek. Dengan demikian prevalensinya adalah 50%.



Diagonal segments are produced by ties.

Interpretasi:

Kurva ROC (Receiver Operating Characteristic) menunjukkan bahwa skor konsentrasi Sandwich ELISA mempunyai nilai diagnostic yang baik karena kurva jauh dari garis 50% dan mendekati 100%.

Area Under the Curve

Test Result Variable(s): KONSENTRASI SANDWICH ELISA

Area	Std. Error[a]	Asymptotic Sig.[b]	Asymptotic 95% Confidence Interval	
			Lower Bound	Upper Bound
,986	,012	,000	,962	1,000

The test result variable(s): KONSENTRASI SANDWICH ELISA has at least one tie between the positive actual state group and the negative actual state group. Statistics may be biased.

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

Interpretasi:

Nilai AUC (Area under the Curve) adalah 98,6% (IK95%; 92,2% - 100%). Nilai AUC 98,6% artinya apabila skor konsentrasi Sandwich ELISA digunakan untuk mendiagnosa ada tidaknya gejala psikotik akibat penyalahgunaan metamfetamin pada 100 orang klien, maka kesimpulan yang tepat akan diperoleh pada 98,6 klien



Coordinates of the Curve

Test Result Variable(s): KONSENTRASI SANDWICH ELISA

No.	Positive if Greater Than or Equal To[a]	Sensitivity	1 - Specificity
1	-,5300	1,000	0,000
2	,4900	1,000	0,033
3	,5300	1,000	0,067
4	,5550	1,000	0,100
5	,6100	1,000	0,133
6	,7000	1,000	0,167
7	,7600	1,000	0,233
8	,8350	1,000	0,267
9	,9250	1,000	0,300
10	,9850	1,000	0,333
11	1,0250	1,000	0,367
12	1,0650	1,000	0,400
13	1,1000	1,000	0,433
14	1,1350	1,000	0,467
15	1,1800	1,000	0,567
16	1,2300	1,000	0,600
17	1,2950	1,000	0,633
18	1,3800	1,000	0,667
19	1,4550	1,000	0,700
20	1,5500	1,000	0,733
21	1,6250	1,000	0,767
22	1,6450	1,000	0,800
23	1,7150	1,000	0,833
24	1,8400	1,000	0,867
25	1,9600	1,000	0,900
26	2,1650	1,000	0,933
27	2,3400	,967	0,933
28	2,3800	,933	0,933
29	2,4150	,900	0,967
30	2,4700	,867	0,967
31	2,5300	,833	0,967
32	2,6450	,767	0,967
33	2,8950	,733	0,967

34	3,0700	,700	0,967
35	3,1500	0,633	1,000
3`6	21	Q`	1,000
37	3,5350	0,567	1,000
38	3,6450	0,533	1,000
39	3,7600	0,500	1,000
40	3,8350	0,467	1,000
41	3,9150	0,433	1,000
42	3,9500	0,400	1,000
43	4,0350	0,367	1,000
44	4,2550	0,333	1,000
45	4,4200	0,300	1,000
46	4,4600	0,267	1,000
47	4,5100	0,233	1,000
48	4,6050	0,200	1,000
49	4,6800	0,133	1,000
50	4,7650	0,100	1,000
51	4,9100	0,067	1,000
52	5,0950	0,033	1,000
53	6,2100	0,000	1,000

The test result variable(s): KADAR SANDWICH ELISA has at least one tie between the positive actual state group and the negative actual state group. The smallest cutoff value is the minimum observed test value minus 1, and the largest cutoff value is the maximum observed test value plus 1. All the other cutoff values are the averages of two consecutive ordered observed test values.

Titik potong (cut-off) yang direkomendasikan secara statistik adalah antara 0,49 sampai 0,55**,** dengan nilai sensitivitas 100% dan spesifisitas ≥ 90%.